Safety First in TB Prevention: Time to Stop Using INH
January 24, 2019
Dick Menzies, MD, MSc, McGill University
Dr. Dick Menzies received his medical training at McGill University, Montreal and specialty training in Internal Medicine at the Medical College of Pennsylvania in Philadelphia, USA. After a 2 ½ year stint in Lesotho, Africa, he received further training in Respiratory Medicine and a Masters degree in Epidemiology & Biostatistics at McGill University. Dr. Menzies has served as Medical Director at the Montreal Chest Institute for a total of 10 years ending in 2002, as Director of the Respiratory Epidemiology Unit at McGill University for 13 years, and as Director of the Respiratory Division for 9 years.
Dr. Menzies has a long history of involvement in tuberculosis care and research, beginning with his years in Lesotho, where tuberculosis is highly endemic. Since his return to Montreal, he has developed a tuberculosis research programme of clinical and epidemiologic studies linked with a large multi-disciplinary clinical service at the Montreal Chest Institute, and the Public Health Unit of Montreal. He developed and lead international collaborative groups in nosocomial transmission of TB, MDR-TB treatment, INH Resistant TB treatment, and large scale randomized trials in 9 countries. Dr. Menzies has also been involved as a consultant to National TB Programs in the Dominican Republic, Guyana and Ecuador, and was on sabbatical at WHO in 2014-15 where he helped develop the Global Action Framework for TB Research. He has worked with WHO and other agencies to develop guidelines for treatment of active and latent Tuberculosis. He has published over 300 peer-reviewed papers and more than 30 book chapters based on the results of his research.